Animal-study meta-analysis finds behavioral effects, but mixed cognition results

Effects of cannabidiol on anxiety- and depressive-like behaviors and cognition: a systematic review and meta-analysis of preclinical studies.

Molecular psychiatry • • Review • Highly Relevant
🤖

AI Summary

This systematic review and meta-analysis examined 123 animal studies to assess whether cannabidiol (CBD) affects anxiety-like and depressive-like behaviors and cognition. Across the preclinical models, CBD consistently reduced anxiety- and depressive-like behaviors, with moderate effects reported in several behavioral tests. These are animal findings, not evidence of treatment effects in people.

Cognitive outcomes were mixed: CBD improved performance in some memory and discrimination tasks, while effects in spatial-memory tests were small or inconsistent. Results often varied by test type and underlying pathology. The abstract reports possible involvement of serotonergic signaling, the endocannabinoid system, and other biological pathways, but says human clinical evidence remains limited and inconclusive. This abstract-based summary cannot establish whether CBD is effective or safe for anxiety, depression, or cognitive problems in people.

💡 Key Findings

1
Across 123 animal studies, CBD consistently reduced anxiety-like and depressive-like behaviors in preclinical tests.
High
85%
2
Cognitive effects were mixed: some task performance improved, while findings in spatial-memory tests were small or inconsistent.
High
85%
3
The abstract reports that effects often depended on the behavioral test and whether underlying pathology was present.
Good
75%
4
The review supports further translational research, but human clinical evidence remains limited and inconclusive.
High
90%

📄 Original Abstract

BACKGROUND: Cannabidiol (CBD) has emerged as a promising neuroprotective compound, with potential benefits for cognitive and emotional behaviors. However, the consistency of its effects across preclinical models remains uncertain. METHODS: We conducted a systematic review and meta-analysis of 123 animal studies assessing the impact of CBD on anxiety-like and depressive-like behaviors, as well as cognition. RESULTS: CBD consistently reduced anxiety- and depressive-like behaviors, with moderate effect sizes observed in paradigms such as the elevated plus maze, novelty suppressed feeding, forced swim, sucrose preference, and tail suspension test. Cognitive effects were more heterogeneous: CBD improved performance in adverse, discriminatory, and working memory tasks, while effects were small or inconsistent in hippocampus-dependent spatial memory tests. Subgroup analyses revealed that CBD's efficacy often depended on the type of behavioral test and the presence of underlying pathologies. Mechanistic evidence implicates serotonergic signaling (notably 5-HT1A receptors), endocannabinoid modulation, anti-inflammatory and neurotrophic pathways, as well as mitochondrial and synaptic plasticity processes, as contributors to these behavioral outcomes. Risk of bias assessment indicated moderate to high quality across studies, confirming the robustness of the findings. CONCLUSIONS: Overall, our results indicate that CBD reduces anxiety-like and depressive-like behaviors and improves cognitive performance across a variety of preclinical models. While these findings support its therapeutic potential and provide a rationale for guiding translational research, clinical evidence in humans is still limited and inconclusive, underscoring the need for further research.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.